Cell Cycle/DNA Damage

You can also try the following methods, and our professionals will serve you Customized Consultation

Cat. No.	Product Name	Field of Application
DC11713	NSC-109555 ditosylate	A potent, selective, reversible, ATP-competitive Chk2 inhibitor with IC50 of 0.2 uM.
DC11716	XL-844	A potent, specific, orally available, ATP‑competitive inhibitor of Chk1 and Chk2 with Ki of 2.2 nM and 0.07 nM, respectively.
DC11759	AKCI	A small-molecule inhibitor that blocks the Aurora C/IκBα interaction (IC50=24.9 uM) and exerts antitumor activity in MDA-MB-231 breast cancer cells.
DC10920	A12B4C3	A12B4C3 (hPNKP inhibitor A12B4C3) is a specific, noncompetitive inhibitor of the human DNA repair enzyme polynucleotide kinase/phosphatase (hPNKP) with C50 of 60 nM, displays no inhibition of calcineurin and protein phosphatase-1 or APTX.
DC7046	A-966492 Featured	A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with Ki of 1 nM and 1.5 nM, respectively.
DC10318	Acelarin Featured	Acelarin (NUC-1031) is a ProTide transformation and enhancement of the widely-used nucleoside analogue, gemcitabine.
DC5106	AG14361 Featured	AG14361 is a potent inhibitor of PARP1 with Ki of <5 nM. It is at least 1000-fold more potent than the benzamides.
DC7164	AG-024322	AG-24322 is a second generation CDK inhibitor. AG-024322 is a potent inhibitor of CDK1, CDK2, and CDK4 that produces cell-cycle arrest and antitumor activity in preclinical models. The no-adverse-effect dose of AG-024322 was 2 mg/kg and associated with ov
DC9838	Alsterpaullone Featured	Alsterpaullone is a potent ATP-competitive and cell cycle cyclin-dependent kinase inhibitor, that is reported to be the most active Paullone.
DC9366	AMG 900 Featured	AMG 900 is a potent and highly selective pan-Aurora kinases inhibitor for Aurora A/B/C with IC50 of 5 nM/4 nM /1 nM; >10-fold selective for Aurora kinases than p38α, Tyk2, JNK2, Met and Tie2.
DC8397	AMG 925 Featured	AMG 925 is a potent and selective dual inhibtor of CDK4/FLT3 with IC50s of 1.5 nM and 2.4 nM for CDK4 and FLT3, respectively; with IC50 of 19 nM in MOLM-13 cell.
DC8923	AS-1413(Amonafide)	Amonafide(AS1413) produces protein-associated DNA-strand breaks through a topoisomerase II-mediated reaction, but does not produce topoisomerase I-mediated DNA cleavage.
DC7510	TAC-101	amsilarotene (TAC-101) is a retinobenzoic acid with potential antineoplastic activity. TAC-101 inhibits retinoblastoma-gene product (RB) phosphorylation and increases the presence of 2 cyclin-dependent kinase (CDK) inhibitors, resulting in cell cycle arrest. This agent also causes a cytotoxic decline in cyclin A and thymidylate synthase expression. Check For active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).For the detailed information of TAC-101, the solubility of TAC-101 in water, the solubility of TAC-101 in DMSO, the solubility of TAC-101 in PBS buffer, the animal experiment (test) of TAC-101, the cell expriment (test) of TAC-101, the in vivo, in vitro and clinical trial test of TAC-101, the EC50, IC50,and Affinity of TAC-101, Please contact DC Chemicals..
DC10950	AOH1160	AOH1160 is a potent, first-in-class, orally available small molecule inhibitor of Proliferating cell nuclear antigen (PCNA).
DC11163	AST-3424 Featured	AST-3424 (OBI-3424, TH-3424) is a first-in-class, novel prodrug that selectively targets cancers overexpressing the enzyme AKR1C3, OBI-3424 is a highly selective prodrug that is converted by AKR1C3 to a DNA alkylating agent.
DC9676	AT7519 Featured	AT7519 is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM; less potent to CDK3 and little active to CDK7.
DC1025	AT7519 HCL Featured	AT7519 is a novel multi-CDK inhibitor for CDK1/cyclin B, CDK2/Cyclin A, CDK3/Cyclin E, CDK4/Cyclin D1, CDK5/p35 and CDK6/Cyclin D3 with IC50 of 210 nM, 47 nM, 360 nM, 100 nM, 13 nM and 170 nM, respectively.
DC9395	AT7519 (trifluoroacetate)	AT7519 trifluoroacetate is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM; less potent to CDK3 and little active to CDK7.
DC7070	AT9283 Featured	AT9283 is a small molecule a multi-targeted inhibitor with of 4, 1.2, 1.1 and approximate 3 nM for Bcr-Abl(T3151), Jak2 and Jak3, aurora A and B, respectively.
DC7964	Aurora A Inhibitor I Featured	Aurora A inhibitor I is a selective Aurora A inhibitor (Aurora A: IC50=0.0034 μM; Aurora B IC50=3.4 μM), (B/A ratio=1000).
DC10906	AZ31 Featured	AZ31 is a novel ATM inhibitor.
DC7072	AZ3146 Featured	AZ3146 is a potent and selective monopolar spindle 1 (Mps1) kinase inhibitor (IC50 = 35 nM); less potent to FAK, JNK1, JNK2, and Kit.
DC10891	AZ-32 Featured	AZ32 is an orally bioavailable and blood-brain-barrier penetrating ATM inhibitor (AZ32) that radiosensitizes intracranial gliomas in mice.
DC7926	AZ-6102 Featured	AZ6102 is a potent TNKS1/2 inhibitor that has 100-fold selectivity against other PARP family enzymes and shows 5 nM Wnt pathway inhibition in DLD-1 cells.
DC10056	AZ9482 Featured	AZ9482, a potent and selective PARP inhibitor featuring an amide linkage to a 2-piperazinyl-3-cyano-pyridine.
DC9309	AZD-0156 Featured	AZD-0156 is an orally bioavailable ataxia telangiectasia mutated (ATM) kinase inhibitor, with potential chemo-/radio-sensitizing and antineoplastic activities.
DC5054	AZD1080 Featured	AZD1080 is a selective, orally active, brain permeable GSK3 inhibitor, inhibits human GSK3α and GSK3β with Ki of 6.9 nM and 31 nM, respectively, shows >14-fold selectivity against CDK2, CDK5, CDK1 and Erk2.
DC7060	AZD1152 Featured	AZD1152 (barasertib), pro-drug of barasertib-hQPA, is a selective Aurora B kinase inhibitor, AZD1152 inhibited the proliferation various types of human leukemia cells with an IC50 ranging from 3 nM to 40 nM.
DC1037	AZD2461 Featured	AZD2461 is indeed a novel poly (ADP-ribose) polymerase (PARP) inhibitor that has been investigated for its potential to overcome resistance mechanisms associated with other PARP inhibitors, such as Olaparib. One of the key resistance mechanisms to Olaparib is mediated by P-glycoprotein (Pgp), an efflux pump that can reduce intracellular concentrations of the drug, thereby diminishing its efficacy.
DC11295	AZD-4573	AZD4573 is a CDK9 inhibitor with an IC50 of <3 nM extracted from patent US 20160376287 A1, example 14.

Cell Cycle/DNA Damage

Customized Consultation X

Your information is safe with us. * Required Fields.